Creative Biolabs, one of the industry-pioneering CROs holding specialties in bioconjugate, participated in the 13th Annual World ADC Summit last week and announced the successful accomplishment of its journey in San Diego.Read More…
About ADCs Payloads: Innovative Drug
Innovative Drugs Apoptosis inducer (Bcl-xL inhibitor) The overexpression of anti-apoptotic Bcl-2 family members (including Bcl-xL) is one of the mechanisms by which cancer cells acquire apoptosis resistance. Drugs that block the BH3-bindingRead More…
About ADCs Payloads: DNA-damaging Drug
DNA-damaging Drugs Pyrrolobenzodiazepine and Indolinobenzodiazepine Pyrrolobenzodiazepines (PBD) is a kind of natural product with antineoplastic activity. Their mode of action is selective alkylation in a small groove of DNA, in which guanineRead More…
About ADCs Payloads: Microtubule-destroying Drug
Antibody-drug conjugate (ADC) is formed by linking monoclonal antibodies targeting specific antigens with small molecular cytotoxic drugs through linkers, which have both the strong killing effect of traditional small molecule chemotherapy andRead More…
NEJM: ADC Drug for Advanced Breast Cancer Treatment Shows Amazing Effect
Breast cancer is the most common cancer among women. In 2020, breast cancer has replaced lung cancer as the number one cancer in the world. The latest global cancer burden data forRead More…
The Review of New Drug Conjugates
With the approval of a number of ADC drugs around the world since 2019, conjugated drugs have developed into one of the hottest tracks in the pharmaceutical industry. Not only traditional ADCRead More…
New structures to resolve the instability of Maleimide joint
An ADC consists of an antibody and toxin bridged by a linker that affects the coupling stability to some extent and has an important influence on ADC efficacy. The premature release ofRead More…
Ushering in a “Raging” Era—Fiercely Competitive Phase III ADCs (part I)
An antibody-drug conjugate (ADC) is composed of an antibody, a chemical linker, and a small molecular payload, and takes advantage of the specific targeting binding ability of antibody to transport cytotoxic payloadRead More…
Analytical methods of average drug to antibody ratio (DAR) of antibody-drug conjugates
Antibody-drug conjugate (ADC) is a new type of biological targeting drug for the cancer treatment, which perfectly combines the high specificity of antibody and the strong lethal power of cytotoxin. With theRead More…
Unprecedented!—FDA accelerates the approval of CD19-ADC
Recently, FDA has accelerated the approval of ADC Therapeutics’ targeted CD19-ADC drug Loncastuximab tesirine for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). It is worth mentioning that,Read More…